FDG autoradiography reveals developmental and pathological effects of mutant amyloid in PDAPP transgenic mice
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Transgenic mouse models of Alzheimer's disease (AD) show some characteristic features of the disease, and we aim to further bridge the gap between studies of humans with AD, those at risk, and these murine models by providing shared markers of disease which could be used to track progression and assess future interventions. Brain imaging measurements may prove useful in this regard. We previously found that the homozygous PDAPP mouse model of AD showed significant declines in glucose uptake with age in posterior cingulate cortex (PCC), an area homologous to the human posterior cingulate, which shows significant declines in AD and in those at risk for AD. To further evaluate this potential biomarker and its correlation across age, we used fluorodeoxyglucose (FDG) autoradiography at two ages (2 and 12 months) in wildtype, heterozygous, and homozygous PDAPP mice. We found significant posterior cingulate fluorodeoxyglucose uptake declines again in homozygous PDAPP mice, but at both ages assessed. There was a strong effect of gene dose; homozygous mice showed larger and earlier effects. These results, in conjunction with our previous analyses, indicate a nonlinear progression stemming from synergistic effects of the overexpressed mutant gene, both developmental and pathological. The posterior cingulate is preferentially vulnerable to both effects of transgene in the PDAPP mouse, and both are independent of amyloid deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420114 · Cited by 1,802 · cited 1×
“…Alzheimer’s disease (AD) characteristically show preferential and progressive neocortical reductions in measurements of the cerebral metabolic rate for glucose or FDG uptake, with the largest reduction found in the posterior cingulate cortex (PCC; Minoshima et al., 1994, 1997; Reiman et al., 1996).”
BackgroundHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366 · cited 1×
“…Alzheimer’s disease (AD) characteristically show preferential and progressive neocortical reductions in measurements of the cerebral metabolic rate for glucose or FDG uptake, with the largest reduction found in the posterior cingulate cortex (PCC; Minoshima et al., 1994, 1997; Reiman et al., 1996).”
BackgroundSelf-citationA learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease
Chen, G., Chen, K. S., Knox, J., Inglis, J., Bernard, A., Martin, S. J., Justice, A., McConlogue, L., Games, D., Freedman, S. B., et al. (2000) · Nature · doi:10.1038/35050103 · Cited by 740
Klunk, W. E., Price, J. C., Mathis, C. A., Tsopelas, N. D., Lopresti, B. J., Ziolko, S. K., Bi, W., Hoge, J. A., Cohen, A. D., Ikonomovic, M. D., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0730-07.2007 · Cited by 389
Intraneuronal Aβ accumulation and origin of plaques in Alzheimer's disease
Gouras, G. K., Almeida, C. G., & Takahashi, R. H. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.05.022 · Cited by 338 · cited 1×
“There is also increasing support for the role of soluble and/or intracellular APP products in the disruption of cellular processes in AD (Gouras et al., 2005, for review) as well as in transgenic animal models (Galvan et al., 2006).”
BackgroundPosterior cingulate cortex in Alzheimer's disease
MINOSHIMA, S. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92871-1 · Cited by 316 · cited 1×
“…Alzheimer’s disease (AD) characteristically show preferential and progressive neocortical reductions in measurements of the cerebral metabolic rate for glucose or FDG uptake, with the largest reduction found in the posterior cingulate cortex (PCC; Minoshima et al., 1994, 1997; Reiman et al., 1996).”
BackgroundGalvan, V., Gorostiza, O. F., Banwait, S., Ataie, M., Logvinova, A. V., Sitaraman, S., Carlson, E., Sagi, S. A., Chevallier, N., Jin, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509695103 · Cited by 239
Sabo, S. L., Ikin, A. F., Buxbaum, J. D., & Greengard, P. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-13-05407.2003 · Cited by 187 · cited 2×
“We have attributed this callosal defect to potential interference with APP’s normal role in axonal growth cone motility (Sabo et al., 2003).”
BackgroundTracking Alzheimerʼs disease in transgenic mice using fluorodeoxyglucose autoradiography
Reiman, E. M., Uecker, A., Gonzalez-Lima, F., Minear, D., Chen, K., Callaway, N. L., Berndt, J. D., & Games, D. (2000) · NeuroReport · doi:10.1097/00001756-200004070-00018 · Cited by 62 · cited 6×
“We have demonstrated that the homozygous PDAPP transgenic mouse model of AD (Games et al., 1995) reliably shows significant posterior cingulate hypometabolism, in agreement with previous studies (Dodart et al., 1999; Reiman et al., 2000).”
BackgroundResultSelf-citation
Cited by
Estrogen: A master regulator of bioenergetic systems in the brain and body
Rettberg, J. R., Yao, J., & Brinton, R. D. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.08.001 · Cited by 534
The role of glucose transporters in brain disease: Diabetes and Alzheimer’s disease
Shah, K., DeSilva, S., & Abbruscato, T. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012629 · Cited by 288
Zhao, W.-Q., & Townsend, M. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.10.014 · Cited by 291
Nicholson, R. M., Kusne, Y., Nowak, L. A., LaFerla, F. M., Reiman, E. M., & Valla, J. (2010) · Brain Research · doi:10.1016/j.brainres.2010.05.084 · Cited by 107
Self-citationA review of β-amyloid neuroimaging in Alzheimer's disease
Adlard, P. A., Tran, B. A., Finkelstein, D. I., Desmond, P. M., Johnston, L. A., Bush, A. I., & Egan, G. F. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00327 · Cited by 93
“Following the development of functional FDG PET imaging in patients with AD, the feasibility of detecting and monitoring similar changes in cerebral metabolism in AD mouse models was investigated (Reiman and Caselli, 1999; Valla et al., 2002, 2006, 2008; Dubois et al., 2010; Nicholson et al., 2010).”
MethodResultEarly Detection of Cerebral Glucose Uptake Changes in the 5XFAD Mouse
Macdonald, I. R., DeBay, D. R., Reid, G. A., O’Leary, T. P., Jollymore, C. T., Mawko, G., Burrell, S., Martin, E., Bowen, C. V., Brown, R. E., et al. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666140505111354 · Cited by 79
Do, T. M., Alata, W., Dodacki, A., Traversy, M.-T., Chacun, H., Pradier, L., Scherrmann, J.-M., Farinotti, R., Calon, F., & Bourasset, F. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.02.010 · Cited by 77
Metadata
- Authors
- Valla, J., Gonzalez‐Lima, F., & Reiman, E. M.
- Venue
- International Journal of Developmental Neuroscience
- Publisher
- Wiley
- Published
- 2008-02-15
- Volume
- 26
- Issue
- 3-4
- Pages
- 253-258
- ISSN
- 0736-5748 (ISSN-L)
- 1873-474X
- OpenAlex
- W2046114197
- Cited by
- 34
- References
- 10
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.